Articles by Matthew Campbell, MD, MS
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
The impact of squamous and other histologies on outcomes with EV are dissected.
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.